Vikram Purohit
Stock Analyst at Morgan Stanley
(0.84)
# 3,802
Out of 4,884 analysts
170
Total ratings
26.67%
Success rate
-10.54%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $5.27 | -5.12% | 4 | Jul 3, 2025 | |
| HALO Halozyme Therapeutics | Downgrades: Equal-Weight | $73 → $62 | $54.00 | +14.81% | 7 | May 14, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $174.18 | +43.53% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $68.45 | -5.04% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $105.44 | +80.20% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $10.03 | +248.95% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.13 | +75.44% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $20.30 | +52.71% | 2 | Sep 11, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.77 | +152.71% | 1 | Jul 3, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $7.96 | +101.01% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.26 | +820.25% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $9.20 | +139.13% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $13.82 | -27.64% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.08 | +188.46% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.74 | +380.55% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $1.23 | +1,729.27% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $44.79 | -8.46% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $27.50 | +45.45% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $0.64 | +1,940.18% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $21.12 | +79.92% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.33 | +76.52% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $11.15 | -10.31% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $29.73 | -76.45% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.51 | +1,356.95% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $11.60 | +72.41% | 2 | Aug 5, 2020 |
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $5.27
Upside: -5.12%
Halozyme Therapeutics
May 14, 2025
Downgrades: Equal-Weight
Price Target: $73 → $62
Current: $54.00
Upside: +14.81%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $174.18
Upside: +43.53%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $68.45
Upside: -5.04%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $105.44
Upside: +80.20%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $10.03
Upside: +248.95%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.13
Upside: +75.44%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $20.30
Upside: +52.71%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.77
Upside: +152.71%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $7.96
Upside: +101.01%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $3.26
Upside: +820.25%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $9.20
Upside: +139.13%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $13.82
Upside: -27.64%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.08
Upside: +188.46%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.74
Upside: +380.55%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $1.23
Upside: +1,729.27%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $44.79
Upside: -8.46%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $27.50
Upside: +45.45%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $0.64
Upside: +1,940.18%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $21.12
Upside: +79.92%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.33
Upside: +76.52%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $11.15
Upside: -10.31%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $29.73
Upside: -76.45%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.51
Upside: +1,356.95%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $11.60
Upside: +72.41%